Sanaa A Alsubheen, Myanca Rodrigues, Kristian Thorlund
{"title":"固定剂量噻托溴铵/奥替特罗联合治疗对慢性阻塞性肺疾病患者运动相关结局指标的影响：一项系统综述和荟萃分析","authors":"Sanaa A Alsubheen, Myanca Rodrigues, Kristian Thorlund","doi":"10.1080/17476348.2025.2522754","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction/objectives: </strong>This systematic review aimed to summarize the evidence on the effect of the fixed-dose combination of tiotropium/olodaterol (Tio/Olo 5/5 μg FDC) on exercise-related outcome measures.</p><p><strong>Methods: </strong>We included randomized clinical trials (RCTs) from four databases that investigated the effectiveness of Tio/Olo 5/5 μg FDC on exercise tolerance, breathlessness, lung function, and physical activity from inception to October 2024.</p><p><strong>Results: </strong>Findings from eight RCTs indicated that Tio/Olo 5/5 μg FDC was superior to Tio 5 μg or placebo for the following outcomes: exercise tolerance [Tio 5 μg: 3 RCTs, mean difference (MD) = 16.6 m, 95% CI: 5.2-28.1, <i>p</i> < 0.001], exercise endurance time [Placebo: 2 RCTs, SMD = 0.29, 95% CI: 0.19-0.39, <i>p</i> = <i>p</i> < 0.001], inspiratory capacity [Tio 5 μg: 3 RCTs, MD = 0.13 L, 95% CI: 0.07-0.19, <i>p</i> < 0.001], and forced expiratory volume in 1 second (FEV<sub>1</sub>) [Tio 5 μg: 4 RCTs, MD = 0.12 L, 95% CI: 0.11-0.14, <i>p</i> < 0.001; Placebo: 2 RCTs, MD = 0.33 L, 95% CI: 0.3-0.35, <i>p</i> < 0.001], with no effect on physical activity levels.</p><p><strong>Conclusion: </strong>Tio/Olo 5/5 μg FDC compared to Tio 5 μg or placebo may improve exercise tolerance and lung function, but not physical activity levels in COPD.</p><p><strong>Protocol registration: </strong>The systematic review protocol is registered on PROSPERO (International Prospective Register of Systematic Reviews): number CRD42024598553.</p>","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1-12"},"PeriodicalIF":2.7000,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effect of fixed-dose tiotropium/olodaterol combined therapy on exercise-related outcome measures in individuals with chronic obstructive pulmonary disease: a systematic review and meta-analysis.\",\"authors\":\"Sanaa A Alsubheen, Myanca Rodrigues, Kristian Thorlund\",\"doi\":\"10.1080/17476348.2025.2522754\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction/objectives: </strong>This systematic review aimed to summarize the evidence on the effect of the fixed-dose combination of tiotropium/olodaterol (Tio/Olo 5/5 μg FDC) on exercise-related outcome measures.</p><p><strong>Methods: </strong>We included randomized clinical trials (RCTs) from four databases that investigated the effectiveness of Tio/Olo 5/5 μg FDC on exercise tolerance, breathlessness, lung function, and physical activity from inception to October 2024.</p><p><strong>Results: </strong>Findings from eight RCTs indicated that Tio/Olo 5/5 μg FDC was superior to Tio 5 μg or placebo for the following outcomes: exercise tolerance [Tio 5 μg: 3 RCTs, mean difference (MD) = 16.6 m, 95% CI: 5.2-28.1, <i>p</i> < 0.001], exercise endurance time [Placebo: 2 RCTs, SMD = 0.29, 95% CI: 0.19-0.39, <i>p</i> = <i>p</i> < 0.001], inspiratory capacity [Tio 5 μg: 3 RCTs, MD = 0.13 L, 95% CI: 0.07-0.19, <i>p</i> < 0.001], and forced expiratory volume in 1 second (FEV<sub>1</sub>) [Tio 5 μg: 4 RCTs, MD = 0.12 L, 95% CI: 0.11-0.14, <i>p</i> < 0.001; Placebo: 2 RCTs, MD = 0.33 L, 95% CI: 0.3-0.35, <i>p</i> < 0.001], with no effect on physical activity levels.</p><p><strong>Conclusion: </strong>Tio/Olo 5/5 μg FDC compared to Tio 5 μg or placebo may improve exercise tolerance and lung function, but not physical activity levels in COPD.</p><p><strong>Protocol registration: </strong>The systematic review protocol is registered on PROSPERO (International Prospective Register of Systematic Reviews): number CRD42024598553.</p>\",\"PeriodicalId\":94007,\"journal\":{\"name\":\"Expert review of respiratory medicine\",\"volume\":\" \",\"pages\":\"1-12\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2025-06-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert review of respiratory medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/17476348.2025.2522754\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert review of respiratory medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17476348.2025.2522754","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
前言/目的：本系统综述旨在总结噻托溴铵/奥洛daterol （Tio/Olo 5/5 μg FDC）固定剂量组合对运动相关指标影响的证据。方法：我们纳入了来自四个数据库的随机临床试验（rct），研究了Tio/Olo 5/5 μg FDC从开始到2024年10月对运动耐量、呼吸困难、肺功能和身体活动的有效性。八个相关的结果:结果表明Tio /卡5/5μg FDC优于Tio 5μg或安慰剂下列结果:运动公差(Tio 5μg: 3相关,平均差(MD) = 16.6米,95%置信区间CI: 5.2 - 28.1, p = p p 1页)(Tio 5μg: 4相关,MD = 0.12 L, 95%置信区间CI: 0.11 - 0.14, p p结论:Tio /卡5/5μg FDC Tio 5μg或安慰剂相比可以提高运动耐量和肺功能,但不是身体活动水平在慢性阻塞性肺病。方案注册：系统评价方案在PROSPERO（国际前瞻性系统评价注册）上注册：编号CRD42024598553。
Effect of fixed-dose tiotropium/olodaterol combined therapy on exercise-related outcome measures in individuals with chronic obstructive pulmonary disease: a systematic review and meta-analysis.
Introduction/objectives: This systematic review aimed to summarize the evidence on the effect of the fixed-dose combination of tiotropium/olodaterol (Tio/Olo 5/5 μg FDC) on exercise-related outcome measures.
Methods: We included randomized clinical trials (RCTs) from four databases that investigated the effectiveness of Tio/Olo 5/5 μg FDC on exercise tolerance, breathlessness, lung function, and physical activity from inception to October 2024.
Results: Findings from eight RCTs indicated that Tio/Olo 5/5 μg FDC was superior to Tio 5 μg or placebo for the following outcomes: exercise tolerance [Tio 5 μg: 3 RCTs, mean difference (MD) = 16.6 m, 95% CI: 5.2-28.1, p < 0.001], exercise endurance time [Placebo: 2 RCTs, SMD = 0.29, 95% CI: 0.19-0.39, p = p < 0.001], inspiratory capacity [Tio 5 μg: 3 RCTs, MD = 0.13 L, 95% CI: 0.07-0.19, p < 0.001], and forced expiratory volume in 1 second (FEV1) [Tio 5 μg: 4 RCTs, MD = 0.12 L, 95% CI: 0.11-0.14, p < 0.001; Placebo: 2 RCTs, MD = 0.33 L, 95% CI: 0.3-0.35, p < 0.001], with no effect on physical activity levels.
Conclusion: Tio/Olo 5/5 μg FDC compared to Tio 5 μg or placebo may improve exercise tolerance and lung function, but not physical activity levels in COPD.
Protocol registration: The systematic review protocol is registered on PROSPERO (International Prospective Register of Systematic Reviews): number CRD42024598553.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
